<DOC>
	<DOC>NCT00568139</DOC>
	<brief_summary>Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many side effects are not well documented. Therefore, we are aiming at collecting data about side effects in patients treated with mitotane</brief_summary>
	<brief_title>Evaluation of Side Effects of Mitotane</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Mitotane</mesh_term>
	<criteria>Adrenocortical carcinoma Treatment with mitotane intended or mitotane administered</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adrenal cancer</keyword>
	<keyword>mitotane (Lysodren)</keyword>
	<keyword>adverse events</keyword>
</DOC>